The Neural Correlates of Cannabis Use

NCT03104257 | Completed FDA Drug

• 2 other identifiers: 13080125141R01DA040698-01A1
• Study Type: observational
• Target: 162
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to determine the temporal course of recovery of CB1R availability and neural oscillations, in cannabis-dependent individuals at baseline, following 48 hour confirmed inpatient abstinence and after four weeks confirmed abstinence. This research will also examine associations between CB1R availability, neural oscillations and cognitive function.

Conditions

Cannabis Dependence; Healthy

Keywords

Healthy Control, Cannabis, Dependence

Outcome Measures

Primary Outcomes (1)

• CB1R availability using [11-C]OMAR PET imaging

  Change in CB1R availability (e.g. volume distribution).

  Change in CB1R availability from baseline to 48 hours and 28 days

Secondary Outcomes (2)

• Changes in Cognition during withdrawal using a computerized battery

  Change in CB1R availability from baseline to 48 hours and 28 days

• Changes in brain rhythms measured by Electroencephalography

  Change in CB1R availability from baseline to 48 hours and 28 days

Study Arms (2)

Cannabis Dependent Subjects

Subjects who are frequent cannabis users

Drug: [11-C]OMAR

Healthy Controls

Subjects with no current cannabis use

Drug: [11-C]OMAR

Interventions

[11-C]OMAR DRUG

The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Cannabis Dependent Subjects; Healthy Controls

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Research subjects can be both cannabis-using or non-cannabis using males and females between the ages of 18-65.

You may qualify if:

• Current cannabis consumption
• Willing to abstain from cannabis use for four weeks
• No current cannabis consumption

You may not qualify if:

• Education completed is less than 12 years

Sponsors & Collaborators

• Yale University: lead
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (1)

Conneticut Mental Health Center

New Haven, Connecticut, 06519, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

When specimens and information are stored, researchers are careful to try to protect your identity from discovery by others. Samples and information will receive a unique code. Other researchers will only receive coded samples and information, and will not be able to link the code to subjects. Strict security safeguards are in place to reduce the chance of misuse or unplanned release of information.

MeSH Terms

Conditions

Marijuana Abuse

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Mohini Ranganathan, MD

  Yale University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: December 22, 2016
• First Posted: April 7, 2017
• Study Start: December 1, 2016
• Primary Completion: April 27, 2022
• Study Completion: April 27, 2022
• Last Updated: October 21, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)